279 related articles for article (PubMed ID: 25537990)
21. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?
Jansen NL; Graute V; Armbruster L; Suchorska B; Lutz J; Eigenbrod S; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1021-9. PubMed ID: 22491781
[TBL] [Abstract][Full Text] [Related]
22. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas.
Gempt J; Bette S; Ryang YM; Buchmann N; Peschke P; Pyka T; Wester HJ; Förster S; Meyer B; Ringel F
Eur J Radiol; 2015 May; 84(5):955-62. PubMed ID: 25748815
[TBL] [Abstract][Full Text] [Related]
23. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
24. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
[TBL] [Abstract][Full Text] [Related]
25. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.
Jansen NL; Schwartz C; Graute V; Eigenbrod S; Lutz J; Egensperger R; Pöpperl G; Kretzschmar HA; Cumming P; Bartenstein P; Tonn JC; Kreth FW; la Fougère C; Thon N
Neuro Oncol; 2012 Dec; 14(12):1473-80. PubMed ID: 23090986
[TBL] [Abstract][Full Text] [Related]
26. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
27. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.
Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325
[TBL] [Abstract][Full Text] [Related]
28. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
[TBL] [Abstract][Full Text] [Related]
29. Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.
Thon N; Kunz M; Lemke L; Jansen NL; Eigenbrod S; Kreth S; Lutz J; Egensperger R; Giese A; Herms J; Weller M; Kretzschmar H; Tonn JC; la Fougère C; Kreth FW
Int J Cancer; 2015 May; 136(9):2132-45. PubMed ID: 25311315
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma.
Jeong SY; Lim SM
Nucl Med Biol; 2012 Oct; 39(7):977-81. PubMed ID: 22483845
[TBL] [Abstract][Full Text] [Related]
31. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.
Pöpperl G; Kreth FW; Mehrkens JH; Herms J; Seelos K; Koch W; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1933-42. PubMed ID: 17763848
[TBL] [Abstract][Full Text] [Related]
32. Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.
Galldiks N; Unterrainer M; Judov N; Stoffels G; Rapp M; Lohmann P; Vettermann F; Dunkl V; Suchorska B; Tonn JC; Kreth FW; Fink GR; Bartenstein P; Langen KJ; Albert NL
Neuro Oncol; 2019 Oct; 21(10):1331-1338. PubMed ID: 31077276
[TBL] [Abstract][Full Text] [Related]
33. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
[TBL] [Abstract][Full Text] [Related]
34. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.
Tscherpel C; Dunkl V; Ceccon G; Stoffels G; Judov N; Rapp M; Meyer PT; Kops ER; Ermert J; Fink GR; Shah NJ; Langen KJ; Galldiks N
Neuro Oncol; 2017 May; 19(5):710-718. PubMed ID: 28039366
[TBL] [Abstract][Full Text] [Related]
35. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
[TBL] [Abstract][Full Text] [Related]
36. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.
Rosen J; Stoffels G; Lohmann P; Bauer EK; Werner JM; Wollring M; Rapp M; Felsberg J; Kocher M; Fink GR; Langen KJ; Galldiks N
Sci Rep; 2021 Oct; 11(1):20828. PubMed ID: 34675225
[TBL] [Abstract][Full Text] [Related]
38. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.
Floeth FW; Sabel M; Stoffels G; Pauleit D; Hamacher K; Steiger HJ; Langen KJ
J Nucl Med; 2008 May; 49(5):730-7. PubMed ID: 18413396
[TBL] [Abstract][Full Text] [Related]
40. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]